[
  {
    "trial": "T022",
    "source": "fulltext",
    "arms": {
      "C group": {"randomized": null, "analysed": "153"},
      "S group (S-ketamine)": {"randomized": null, "analysed": "122"}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": -1, "form": "mean_sd", "location": "Table 1 (EPDS score before surgery)",
       "values": {"C group": {"mean": "6.54", "sd": "2.35", "n": "153"}, "S group (S-ketamine)": {"mean": "6.72", "sd": "2.25", "n": "122"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 3, "form": "mean_sd", "location": "Results, Secondary outcome paragraph",
       "values": {"C group": {"mean": "7.65", "sd": "3.14"}, "S group (S-ketamine)": {"mean": "6.00", "sd": "2.47"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "mean_sd", "location": "Results, Secondary outcome paragraph",
       "values": {"C group": {"mean": "7.62", "sd": "3.14"}, "S group (S-ketamine)": {"mean": "6.38", "sd": "2.67"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 3, "form": "count", "definition": "EPDS ≥ 10", "location": "Results, Primary outcome paragraph (percentages only)",
       "values": {"C group": {"percent": "24.2"}, "S group (S-ketamine)": {"percent": "17.6"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "count", "definition": "EPDS ≥ 10", "location": "Results, Primary outcome paragraph (percentages only)",
       "values": {"C group": {"percent": "9.8"}, "S group (S-ketamine)": {"percent": "8.2"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "values": {"C group": {"dizziness": "14"}, "S group (S-ketamine)": {"dizziness": "15"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2019-09-01", "end": "2020-07-15"},
    "registration": {"number": "ChiCTR2100050263", "date": "2021-08-24"},
    "note": "Randomized numbers per arm are not in the text (Fig. 1 flowchart has no printed numbers); analysed = Table 1 column n (275 analysed after 71 vaginal deliveries, 53 refusals and 52 lost to follow-up). Baseline EPDS: Table 1 gives C 6.54 ± 2.35, S 6.72 ± 2.25 (P 0.48); the Results text says 'similar between the S group and C group before delivery (6.54 ± 2.35 vs. 6.72 ± 2.25, P = 0.508)', naming S first but with Table 1's C-first values; table values and arms taken, P values differ (0.48 vs 0.508). Day 3 and 14 EPDS means in the same paragraph carry no arm labels ('7.65 ± 3.14 vs. 6.00 ± 2.47'; '7.62 ± 3.14 vs. 6.38 ± 2.67'); assigned C first, S second, following the baseline values' order (which matches Table 1) and the lower PPD rate reported for S, so the arm assignment is an inference. n at days 3 and 14 not printed. PPD rate (EPDS ≥ 10) printed only as percentages with no counts ('lower in the S group ... (17.6 and 8.2% vs. 24.2 and 9.8%)'). Day 28 EPDS scores and rates appear only in Figs 2-3 without printed values. VAS at 4-48 h only in Fig. 4a (no values). Table 2 AE row 'Dizzy' coded as dizziness; other rows (headache, nausea, drowsiness, vomit) not in the codebook's categories. Trial retrospectively registered."
  },
  {
    "trial": "T032",
    "source": "fulltext",
    "arms": {
      "Esketamine": {"randomized": "92", "analysed": "92"},
      "Saline": {"randomized": "91", "analysed": "91"}
    },
    "depression": [
      {"measure": "HADS depression subscale (HADS-D)", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Esketamine": {"median": "3", "q1": "2", "q3": "4", "n": "92"}, "Saline": {"median": "3", "q1": "2", "q3": "4", "n": "91"}}},
      {"measure": "HADS depression subscale (HADS-D)", "day": 1, "form": "median_iqr", "location": "Table 2 (POD 1)",
       "values": {"Esketamine": {"median": "2", "q1": "2", "q3": "3", "n": "92"}, "Saline": {"median": "2", "q1": "2", "q3": "3", "n": "91"}}},
      {"measure": "HADS depression subscale (HADS-D)", "day": 3, "form": "median_iqr", "location": "Table 2 (POD 3)",
       "values": {"Esketamine": {"median": "2", "q1": "2", "q3": "3", "n": "92"}, "Saline": {"median": "2", "q1": "2", "q3": "2", "n": "91"}}}
    ],
    "pain": [
      {"measure": "VAS on movement", "day": 1, "form": "median_iqr", "location": "Results, paragraph after Figure 2 (24 hours)",
       "values": {"Esketamine": {"median": "3", "q1": "3", "q3": "4"}, "Saline": {"median": "4", "q1": "3", "q3": "5"}}},
      {"measure": "VAS on movement", "day": 2, "form": "median_iqr", "location": "Results, paragraph after Figure 2 (48 hours)",
       "values": {"Esketamine": {"median": "2", "q1": "2", "q3": "3"}, "Saline": {"median": "3", "q1": "2", "q3": "3"}}},
      {"measure": "hydromorphone consumption at 24 and 48 h", "day": 1, "form": "median_iqr", "location": "Results, paragraph after Figure 2 (first 24 hours, mg)",
       "values": {"Esketamine": {"median": "3.0", "q1": "2.8", "q3": "3.3"}, "Saline": {"median": "3.2", "q1": "2.9", "q3": "3.4"}}},
      {"measure": "hydromorphone consumption at 24 and 48 h", "day": 2, "form": "median_iqr", "location": "Results, paragraph after Figure 2 (total within 48 hours, mg)",
       "values": {"Esketamine": {"median": "5.9", "q1": "5.5", "q3": "6.5"}, "Saline": {"median": "6.1", "q1": "5.7", "q3": "6.7"}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2021-08", "end": "2022-04"},
    "registration": null,
    "note": "Randomized copied from the Results ('183 patients were randomized into 2 groups: control group (n = 91 ...) and esketamine group (n = 92 ...)'), but the Methods say 184 were included (200 assessed, 16 excluded) and the Results say 1 control patient had data loss on POD 3, with a per-protocol analysis, so the control arm may have had 92 randomized and 91 analysed. Tables 1-2 head the columns Control n = 91, Esketamine n = 92; those n are copied for every time, including POD 3. VAS at rest at 24 and 48 h: no numbers (only 'no significant differences'; eTable 2 not in the source). Hydromorphone day 2 is the cumulative total within 48 h. Pain n not printed. AEs: 'Only 1 patient reported having a nightmare' with the arm not stated (eTable 3 not in the source); nausea/vomiting, dizziness and itching 'not significantly different' without counts; nothing coded. Enrollment dates from the Methods (surgery from August 2021 to April 2022); the Results give none. No registration number in the text."
  },
  {
    "trial": "T051",
    "source": "library",
    "arms": {
      "P group (propofol alone)": {"randomized": "35", "analysed": "35"},
      "S group (propofol with esketamine)": {"randomized": "35", "analysed": "35"}
    },
    "depression": [
      {"measure": "EPDS", "day": -1, "form": "mean_sd", "location": "Results (section 3), EPDS paragraph",
       "values": {"P group (propofol alone)": {"mean": "12", "sd": "2.47"}, "S group (propofol with esketamine)": {"mean": "12.46", "sd": "2.73"}}},
      {"measure": "EPDS", "day": 7, "form": "mean_sd", "location": "Results (section 3), EPDS paragraph; same values in abstract",
       "values": {"P group (propofol alone)": {"mean": "8.63", "sd": "3.14"}, "S group (propofol with esketamine)": {"mean": "6.34", "sd": "2.87"}}},
      {"measure": "EPDS", "day": 42, "form": "mean_sd", "location": "Results (section 3), EPDS paragraph",
       "values": {"P group (propofol alone)": {"mean": "9.4", "sd": "2.67"}, "S group (propofol with esketamine)": {"mean": "5.31", "sd": "2.49"}}},
      {"measure": "EPDS", "day": -1, "form": "count", "definition": "EPDS ≥ 10", "location": "Results (section 3), EPDS paragraph",
       "values": {"P group (propofol alone)": {"events": "35"}, "S group (propofol with esketamine)": {"events": "35"}}},
      {"measure": "EPDS", "day": 7, "form": "count", "definition": "EPDS ≥ 10", "location": "Results (section 3), EPDS paragraph",
       "values": {"P group (propofol alone)": {"events": "13"}, "S group (propofol with esketamine)": {"events": "3"}}},
      {"measure": "EPDS", "day": 42, "form": "count", "definition": "EPDS ≥ 10", "location": "Results (section 3), EPDS paragraph",
       "values": {"P group (propofol alone)": {"events": "13"}, "S group (propofol with esketamine)": {"events": "2"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "overall", "values": {"P group (propofol alone)": {"agitation": "0"}, "S group (propofol with esketamine)": {"agitation": "2"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-03", "end": "2022-08"},
    "registration": {"number": "ChiCTR2200058731", "date": null},
    "note": "Source is a PDF text layer; EPDS numbers are in the Results text only (no table). Per group: 'EPDS scores ... ≥10 scores on 1d (n = 35) before the operation and 7d (n = 13), and 42d (n = 13) after the operation, Mean scores were 12 ± 2.47, 8.63 ± 3.14, and 9.4 ± 2.67' (P group); the '(n = ...)' are counts with EPDS ≥ 10 (all 105 had preoperative EPDS ≥ 10 by inclusion), coded as events. The number assessed at each time is not printed; all 35 per group were analysed with 'no lapses in the blinding and follow-up' (ITT). Day -1 = preoperative 1 d. The abstract prints the P group's day 42 mean as '9.40 ± 2.67' (Results text '9.4'); the Results value is kept. D group (dezocine, role other) not extracted. VAS measured only preoperatively and 1 h after surgery (abstract: P 3.51 ± 1.12 vs S 2.40 ± 0.81), so no day 1-2 pain. Table 3 'Delirium' (P 0, D 1, S 2) coded as agitation; Table 3 covers complications 'during and after recovery', so window coded overall. Enrollment from the Methods (scheduled from March to August 2022); the Results say only that the final visit was completed on August 15, 2022. Registered 'before patient enrollment', date not given."
  },
  {
    "trial": "T066",
    "source": "fulltext",
    "arms": {
      "Esketamine group (Group E)": {"randomized": null, "analysed": "39"},
      "Normal saline placebo group (Group C)": {"randomized": null, "analysed": "40"}
    },
    "depression": [],
    "pain": [
      {"measure": "NRS pain (1, 2, 6, 12, 24, 48 h after surgery)", "day": 1, "form": "median_iqr", "location": "Table 2 (24 h)",
       "values": {"Esketamine group (Group E)": {"median": "2", "q1": "1", "q3": "3", "n": "39"}, "Normal saline placebo group (Group C)": {"median": "2", "q1": "1", "q3": "3", "n": "40"}}},
      {"measure": "NRS pain (1, 2, 6, 12, 24, 48 h after surgery)", "day": 2, "form": "median_iqr", "location": "Table 2 (48 h)",
       "values": {"Esketamine group (Group E)": {"median": "2", "q1": "1", "q3": "3", "n": "39"}, "Normal saline placebo group (Group C)": {"median": "1.5", "q1": "1", "q3": "2", "n": "40"}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2021-04", "end": "2022-05"},
    "registration": {"number": "ChiCTR2100043935", "date": "2021-03-05"},
    "note": "SDS (and SAS) at PRE, POD1 and POD2 appear only in Figure 3 with no printed values; the text says only that postoperative depression scores in groups L and E were significantly lower than in C, so no depression entries. Randomized per arm not in the text (CONSORT Figure 1 numbers not printed; 137 assessed for eligibility); analysed = Table 1-3 column n (C 40, L 38, E 39). Lidocaine group (role other) not extracted. Perioperative opioid use: Table 3 gives only intraoperative remifentanil (C 518.00 (217.20), E 374.36 (165.88) μg, mean (SD) with 95% CI), day 0, not extracted; no 24 or 48 h opioid data. AEs: only PONV (C 12, L 2, E 4) is counted; the text says 'There were no indications of lidocaine toxicity or esketamine side effects among any participants', which names no codebook category, so nothing coded. Enrollment dates from the Methods (patients undergoing thyroidectomy between April 2021 and May 2022 assessed); the Results give none."
  },
  {
    "trial": "T087",
    "source": "fulltext",
    "arms": {
      "Group K (study group)": {"randomized": "70", "analysed": "70"},
      "Group C (control group)": {"randomized": "70", "analysed": "70"}
    },
    "depression": [
      {"measure": "POMS depression-dejection subscale (within total mood score)", "day": -1, "form": "median_iqr", "location": "Table 1 (POMS Questionnaire, Depression-dejection, before surgery)",
       "values": {"Group K (study group)": {"median": "9,5", "q1": "3,0", "q3": "18,5"}, "Group C (control group)": {"median": "9,0", "q1": "3,0", "q3": "16,3"}}},
      {"measure": "POMS depression-dejection subscale (within total mood score)", "day": 0, "form": "median_iqr", "location": "Table 2 (depression-dejection, 120 min after surgery)",
       "values": {"Group K (study group)": {"median": "5,0", "q1": "2,0", "q3": "15,0"}, "Group C (control group)": {"median": "5,0", "q1": "2,0", "q3": "15,5"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "overall", "values": {"Group K (study group)": {"visual": "2", "psychiatric_any": "0"}, "Group C (control group)": {"psychiatric_any": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-04-01", "end": "2022-09-01"},
    "registration": null,
    "note": "Numbers use decimal commas as printed (e.g. '9,5'). Day -1 = POMS before surgery (Table 1); day 0 = POMS 120 min after surgery (Table 2's lower-case subscale rows under 'Variables during and after surgery'; the text confirms the C group's depression subscale fell after surgery). n not printed in Tables 1-2; analysed 70 per group from Table 3's regression headers (Group-K n = 70, Group-C n = 70). Pain NRS only at 120 min (K 4.0 (0.8), C 4.6 (0.7), mean (SD)), day 0, not extracted. AEs (text): 'Only two patients in group K (2/70 (3%)) suffered headaches and diplopia, while two patients in group C (2/70 (3%)) experienced a headache. Psychomimetic side effects were not reported by any patients.' Visual = 2 in K (unclear whether both patients had both symptoms); diplopia in C not stated, left out; psychiatric_any 0 in both arms from 'not reported by any patients' (zero stated in words, not printed as 0). Window overall (perioperative and postoperative events). No registration number in the text."
  },
  {
    "trial": "T102",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "80", "analysed": "70"},
      "Normal saline control group": {"randomized": "80", "analysed": "70"}
    },
    "depression": [
      {"measure": "EPDS", "day": -1, "form": "median_iqr", "location": "Table 1 (antenatal assessment, EPDS score)",
       "values": {"Esketamine group": {"median": "8", "q1": "6", "q3": "9", "n": "70"}, "Normal saline control group": {"median": "8", "q1": "6", "q3": "9", "n": "70"}}},
      {"measure": "EPDS", "day": 3, "form": "median_iqr", "location": "Table 3 (EPDS score, 3 days postpartum)",
       "values": {"Esketamine group": {"median": "6", "q1": "5", "q3": "9", "n": "70"}, "Normal saline control group": {"median": "8", "q1": "6", "q3": "10", "n": "70"}}},
      {"measure": "EPDS", "day": 7, "form": "median_iqr", "location": "Table 3 (EPDS score, 7 days postpartum)",
       "values": {"Esketamine group": {"median": "7", "q1": "5", "q3": "8.25", "n": "70"}, "Normal saline control group": {"median": "8", "q1": "5", "q3": "12", "n": "70"}}},
      {"measure": "EPDS", "day": 42, "form": "median_iqr", "location": "Table 3 (EPDS score, 42 days postpartum)",
       "values": {"Esketamine group": {"median": "8", "q1": "6", "q3": "10", "n": "70"}, "Normal saline control group": {"median": "8", "q1": "6.75", "q3": "12", "n": "70"}}},
      {"measure": "EPDS", "day": 3, "form": "count", "definition": "incidence of postpartum depression (EPDS cutoff not stated)", "location": "Table 3 (incidence of postpartum depression, 3 days postpartum)",
       "values": {"Esketamine group": {"events": "5", "n": "70"}, "Normal saline control group": {"events": "14", "n": "70"}}},
      {"measure": "EPDS", "day": 7, "form": "count", "definition": "incidence of postpartum depression (EPDS cutoff not stated)", "location": "Table 3 (incidence of postpartum depression, 7 days postpartum)",
       "values": {"Esketamine group": {"events": "5", "n": "70"}, "Normal saline control group": {"events": "15", "n": "70"}}},
      {"measure": "EPDS", "day": 42, "form": "count", "definition": "incidence of postpartum depression (EPDS cutoff not stated)", "location": "Table 3 (incidence of postpartum depression, 42 days postpartum)",
       "values": {"Esketamine group": {"events": "11", "n": "70"}, "Normal saline control group": {"events": "14", "n": "70"}}}
    ],
    "pain": [
      {"measure": "NRS pain", "day": 1, "form": "median_iqr", "location": "Table 4 (24 h postpartum)",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "3", "n": "70"}, "Normal saline control group": {"median": "3", "q1": "3", "q3": "3", "n": "70"}}},
      {"measure": "NRS pain", "day": 2, "form": "median_iqr", "location": "Table 4 (48 h postpartum)",
       "values": {"Esketamine group": {"median": "2", "q1": "2", "q3": "3", "n": "70"}, "Normal saline control group": {"median": "3", "q1": "2", "q3": "3", "n": "70"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "values": {"Esketamine group": {"dizziness": "7", "nightmare": "1", "visual": "2"}, "Normal saline control group": {"dizziness": "5", "nightmare": "0", "visual": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-01", "end": "2025-08"},
    "registration": {"number": "ChiCTR2300078490", "date": null},
    "note": "Randomized 80 per arm from the Figure 1 caption ('160 randomized. Esketamine and control groups each had 80 allocated'); 70 analysed per arm after follow-up losses (caption: 3 control exclusions for unauthorized analgesic use). Baseline EPDS = antenatal assessment (Table 1). The text never states the EPDS cutoff behind 'incidence of postpartum depression' (Table 3); exclusion used preoperative EPDS ≥ 13. Table 3 also prints Hodges-Lehmann median differences and Newcombe ARRs (control minus esketamine), not extracted since arm values are given. Table 4 NRS pain is during movement per the Results text. Rescue analgesia (butorphanol) is given only as a rate within 72 h (esketamine 9 (12.9%), control 19 (27.1%)), not a 24 or 48 h value, so not extracted; 72 h NRS not extracted. AEs from Table 5 (postoperative); control zeros printed as 0."
  },
  {
    "trial": "T105",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "42", "analysed": "39"},
      "Placebo group": {"randomized": "42", "analysed": "38"}
    },
    "depression": [
      {"measure": "HADS-D", "day": 1, "form": "count", "definition": "HADS-D > 7", "location": "Results, Primary outcome paragraph; also abstract (percentages only)",
       "values": {"Esketamine group": {"percent": "7.7"}, "Placebo group": {"percent": "31.6"}}},
      {"measure": "HADS-D", "day": 3, "form": "count", "definition": "HADS-D > 7", "location": "Results, Primary outcome paragraph; also abstract (percentages only)",
       "values": {"Esketamine group": {"percent": "0.0"}, "Placebo group": {"percent": "15.8"}}},
      {"measure": "HADS-D", "day": 1, "form": "median_iqr", "location": "Results, Primary outcome paragraph",
       "values": {"Esketamine group": {"median": "2", "q1": "1", "q3": "3"}, "Placebo group": {"median": "6", "q1": "5", "q3": "8"}}},
      {"measure": "HADS-D", "day": 3, "form": "median_iqr", "location": "Results, Primary outcome paragraph",
       "values": {"Esketamine group": {"median": "1", "q1": "0", "q3": "2"}, "Placebo group": {"median": "5", "q1": "3", "q3": "6"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "values": {"Esketamine group": {"visual": "0", "dizziness": "0", "nightmare": "0"}, "Placebo group": {"visual": "0", "dizziness": "0", "nightmare": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-06-04", "end": "2025-08-26"},
    "registration": {"number": "ChiCTR2400084537", "date": "2024-05-20"},
    "note": "Tables 1-4 and Table S1 are not in the source (captions only); all numbers come from the Results text. Analysed per arm from the abstract ('Seventy-seven patients completed the study (39 in the esketamine group, 38 in the placebo group)'; per-protocol). Incidence of depression (HADS-D > 7) printed only as percentages: POD1 7.7% vs 31.6% (relative risk 0.24, 95% CI 0.08-0.80), POD3 0.0% vs 15.8% (relative risk 0.00, 95% CI 0.00-0.47). The placebo HADS-D values print as '6 [Citation 5-8]' and '5 [Citation 3-6]' (the web page turned the brackets into citation links); read as median 6, IQR 5-8, and median 5, IQR 3-6. Median differences -4 (95% CI -5 to -3) on both days. Baseline HADS-D not in the text. VAS at rest and with movement, rescue analgesia and intraoperative morphine equivalents: 'no significant differences', no numbers (Table 3 and Figure S1 not in the source). AEs within 48 h: 'None of the patients experienced diplopia, dizziness, nightmares, or loss of intraoperative awareness' coded as 0 in both arms (zero stated in words); 'Postoperative delirium or scalp hydrops was observed in only one patient in the esketamine group' not coded, since it can't be told whether that patient had delirium. Blinding not assessed (the authors say no allocation-guessing survey was given)."
  },
  {
    "trial": "T109",
    "source": "fulltext",
    "arms": {
      "Group S (esketamine)": {"randomized": "46", "analysed": "41"},
      "Group C (saline)": {"randomized": "46", "analysed": "39"}
    },
    "depression": [
      {"measure": "HADS-D", "day": -1, "form": "count", "definition": "HADS-D ≥ 8", "location": "Table 3 (Depression incidence, Preoperative)",
       "values": {"Group S (esketamine)": {"events": "7", "n": "41"}, "Group C (saline)": {"events": "6", "n": "39"}}},
      {"measure": "HADS-D", "day": 14, "form": "count", "definition": "HADS-D ≥ 8 at any postoperative time point (POD1 to POD14)", "location": "Table 3 (Depression incidence, Post-operative)",
       "values": {"Group S (esketamine)": {"events": "8", "n": "41"}, "Group C (saline)": {"events": "15", "n": "39"}}},
      {"measure": "HADS-D", "day": 14, "form": "mean_sd", "location": "Results, Emotional Performance paragraph (PPS)",
       "values": {"Group S (esketamine)": {"mean": "4.34", "sd": "2.17"}, "Group C (saline)": {"mean": "5.38", "sd": "2.41"}}}
    ],
    "pain": [
      {"measure": "NRS at rest (AUC over 48 h)", "day": 1, "form": "median_iqr", "location": "Table 5 (NRS 24h)",
       "values": {"Group S (esketamine)": {"median": "2", "q1": "2", "q3": "4", "n": "41"}, "Group C (saline)": {"median": "3", "q1": "2", "q3": "5", "n": "39"}}},
      {"measure": "NRS at rest (AUC over 48 h)", "day": 2, "form": "median_iqr", "location": "Table 5 (NRS 48h)",
       "values": {"Group S (esketamine)": {"median": "1", "q1": "0", "q3": "2", "n": "41"}, "Group C (saline)": {"median": "2", "q1": "1", "q3": "3", "n": "39"}}},
      {"measure": "Sufentanil consumption (first 24h)", "day": 1, "form": "median_iqr", "location": "Table 2",
       "values": {"Group S (esketamine)": {"median": "18", "q1": "12", "q3": "25", "n": "41"}, "Group C (saline)": {"median": "24", "q1": "18", "q3": "32", "n": "39"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "values": {"Group S (esketamine)": {"dizziness": "6", "nightmare": "0", "hallucination": "0"}, "Group C (saline)": {"dizziness": "2", "nightmare": "0", "hallucination": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-11-04", "end": "2024-12-07"},
    "registration": {"number": "NCT06073015", "date": "2023-10-27"},
    "note": "Analysed 41 esketamine and 39 control per the Results text and Tables 1-5; the Figure 1 description says the reverse (41 control, 39 esketamine) and lists different dropouts, so the text and tables are taken. HADS-D preoperative, POD1, POD3 and POD7 scores appear only in Figure 2 and Supplementary Table 1; the figure description lists esketamine 5.2, 4.4, 4.2, 4.4, 4.4 and control 5.1, 5.5, 5.2, 5.4, 5.4 with no SDs, and its POD14 esketamine value (4.4) disagrees with the text (4.34), so these were not extracted. The POD14 mean ± SD in the text carries no arm labels ('4.34 ± 2.17 vs. 5.38 ± 2.41, P=0.043'); assigned esketamine first, as in the preceding HADS-A sentence; PPS N = 80, per-arm n not printed. Postoperative depression incidence (Table 3) counts HADS-D ≥ 8 at any time from POD1 to POD14, coded at day 14. NRS at rest: Table 5 (24 h 2(2-4) vs 3(2-5); 48 h 1(0-2) vs 2(1-3), P 0.194) differs from the Results text (24 h 2 [2-4] vs 2 [2-5]; 48 h 0 [0-2] vs 1 [1-3], P=0.023); table taken. These NRS time points underlie the design's AUC measure; the AUC itself has no printed numbers. 'Sufentanil consumption (first 24h)' is not in the design (source's own name; units not printed). PCA presses in the first 24 h (demand 10 (6-15) vs 14 (9-20); delivered 8 (5-12) vs 11 (7-16)) not extracted. AEs: dizziness from Table 5; 'no cases of nightmares, respiratory depression, seizures, or hallucinations were reported in either group' coded as 0 (zero stated in words)."
  },
  {
    "trial": "T119",
    "source": "fulltext",
    "arms": {
      "ES group": {"randomized": "60", "analysed": "60"},
      "P group (saline)": {"randomized": "60", "analysed": "60"}
    },
    "depression": [
      {"measure": "PHQ-9", "day": -1, "form": "mean_sd", "location": "Table 2 (Baseline)",
       "values": {"ES group": {"mean": "5.3", "sd": "3.70", "n": "60"}, "P group (saline)": {"mean": "5.2", "sd": "2.44", "n": "60"}}},
      {"measure": "PHQ-9", "day": 30, "form": "mean_sd", "location": "Table 2 (POD30-PHQ9)",
       "values": {"ES group": {"mean": "2.2", "sd": "1.54", "n": "60"}, "P group (saline)": {"mean": "3.1", "sd": "1.87", "n": "60"}}},
      {"measure": "PHQ-9", "day": 30, "form": "change_mean_sd", "location": "Table 2 (Change from Baseline, Mean (SD))",
       "values": {"ES group": {"mean": "-3.1", "sd": "3.33", "n": "60"}, "P group (saline)": {"mean": "-2.1", "sd": "2.14", "n": "60"}}},
      {"measure": "PHQ-9", "day": 30, "form": "change_mean_ci", "location": "Table 2 (Change from Baseline, ANCOVA LS Mean (95% CI))",
       "values": {"ES group": {"mean": "-3.07", "lower": "-3.46", "upper": "-2.68", "level": "0.95", "n": "60"}, "P group (saline)": {"mean": "-2.11", "lower": "-2.50", "upper": "-1.72", "level": "0.95", "n": "60"}}},
      {"measure": "PHQ-9", "day": 7, "form": "change_difference", "location": "Table 4 (linear mixed model, P * POD7 interaction)",
       "estimate": "1.25", "lower": "0.45", "upper": "2.05", "level": "0.95", "scale": "mean_difference", "direction": "P group (saline) minus ES group, change from baseline",
       "values": {"ES group": {}, "P group (saline)": {"n": "60"}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "median_iqr", "location": "Table 5 (Total NRS scores on POD1)",
       "values": {"ES group": {"median": "3", "q1": "2", "q3": "3", "n": "60"}, "P group (saline)": {"median": "3", "q1": "2.8", "q3": "3", "n": "60"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "values": {"ES group": {"psychiatric_any": "1"}, "P group (saline)": {"psychiatric_any": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "All 120 randomized completed follow-up (Results). PHQ-9 at POD7 has no arm summaries: only the linear mixed model's group-by-time interaction (Table 4: P * POD7 beta 1.25, 95% CI 0.45 to 2.05), the P-minus-ES difference in change from baseline (positive favours ES), coded as change_difference; Table 4 prints N 60 for P * POD7 and 120 for POD7 overall, no ES n for POD7. The P * POD30 interaction (1.05, 0.25 to 1.85) is not coded because arm values exist at POD30. change_mean_ci is Table 2's ANCOVA-adjusted LS mean change; adjusted difference P - ES 0.96 (95% CI 0.42 to 1.51, P < 0.001). Table 8's overall PHQ-9 subgroup-model mean difference -1.13 (-1.74, -0.53), SMD -0.81, not extracted. Table 5 lists Group P before Group ES. 'Psychiatric symptoms' in Table 6 (within 24 h after surgery): P 0, ES 1 (1.7%), coded psychiatric_any. No enrollment dates or registration number in the source."
  }
]